All In Biotech

Drug Trial Radar · NCT06384261

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jul 22, 2024

Primary completion

Jan 2027

Study completion Jun 2027

Sponsor

Lead sponsor
OncoVerity, Inc.Industry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • CusatuzumabDrug

    CD70 monoclonal antibody

  • VenetoclaxDrug

    BCL-2 inhibitor

  • AzacitidineDrug

    Hypomethylating agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From date of randomization until the date of death from any cause, assessed up to 5 years

Locations

38 sites in 5 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona

  • City of Hope

    Duarte, California

  • University of California Los Angeles

    Los Angeles, California

  • University of Colorado Health - Anschutz Cancer Pavilion - Anschutz Medical Campus

    Aurora, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • University of Miami - Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida

  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando

    Orlando, Florida

  • University of South Florida = Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • The University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • University of Kentucky Chandler Medical Center

    Lexington, Kentucky

  • Norton Healthcare, Inc.

    Louisville, Kentucky

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Hofstra/Northwell Health

    Lake Success, New York

  • Cornell University

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Wake Forest North Carolina

    Winston-Salem, North Carolina

  • Cleveland Clinic - Taussig Cancer Institute

    Cleveland, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • Fred Hutch Seattle Cancer Care Alliance

    Seattle, Washington

  • Medical College of Wisonsin

    Milwaukee, Wisconsin

  • Tom Baker Cancer Center-Alberta Health Services - University of Calgary

    Calgary, Alberta, Canada

  • Stollery Children's Hospital-Walter C Mackenzie Health Sciences Centre - University of Alberta

    Edmonton, Alberta, Canada

  • Vancouver General Hospital, Gordon and Leslie Diamond Health Care Centre

    Vancouver, British Columbia, Canada

  • University of Western Ontario

    London, Ontario, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Saskatchewan Cancer Agency - Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

  • Marien Hospital Duesseldorf

    Düsseldorf, Germany

  • Universitaetsklinik Frankfurt

    Frankfurt, Germany

  • Universitaetsklinik um Schleswig-Holstein, UKSH-Campus Kiel

    Kiel, Germany

  • Hospital De La Santa

    Barcelona, Spain

  • Instituto Catalan de Oncologia - Hospital Duran i Reynals

    Barcelona, Spain

  • Vall d'Hebron Institute of Oncology

    Barcelona, Spain

  • Universidad de Navarra - Clinica Universidad de Navarra

    Pamplona, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Inselspital Bern

    Bern, Switzerland

  • HFR Fribourg - Hopital Cantonal

    Fribourg, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.